Iterum Therapeutics Plc (NASDAQ:ITRM) price on Friday, October 25, rose 60.68% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.88.
A look at the stock’s price movement, the close in the last trading session was $1.17, moving within a range at $1.12 and $2.32. The beta value (5-Year monthly) was 2.251. Turning to its 52-week performance, $2.50 and $0.62 were the 52-week high and 52-week low respectively. Overall, ITRM moved 79.90% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iterum Therapeutics Plc’s market cap currently stands at around $42.69 million, with investors looking forward to this quarter’s earnings report slated for on 2024-Aug-14.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ITRM is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend ITRM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ITRM’s current price about 74.10% and 69.29% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 83.48, while 7-day volatility ratio is 31.34% and 12.98% in the 30-day chart. Further, Iterum Therapeutics Plc (ITRM) has a beta value of 2.28, and an average true range (ATR) of 0.17.
If we refocus on Iterum Therapeutics Plc (NASDAQ:ITRM), historical trading data shows that trading volumes averaged 0.41 over the past 10 days and 317.79K over the past 3 months. The company’s latest data on shares outstanding shows there are 22.71 million shares.
The 3.33% of Iterum Therapeutics Plc’s shares are in the hands of company insiders while institutional holders own 1.47% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.22 million on 2024-09-30, giving us a short ratio of 0.63. The data shows that as of 2024-09-30 short interest in Iterum Therapeutics Plc (ITRM) stood at 98.0 of shares outstanding, with shares short falling to 0.22 million registered in 2024-08-30. Current price change has pushed the stock -4.57% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ITRM stock continues to rise going into the next quarter.
